Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BridgeBio Pharma Inc before investing.

In this article, we go over a few key elements for understanding BridgeBio Pharma Inc’s stock price such as:

• BridgeBio Pharma Inc’s current stock price and volume
• Why BridgeBio Pharma Inc’s stock price changed recently
• Upgrades and downgrades for BBIO from analysts
• BBIO’s stock price momentum as measured by its relative strength

About BridgeBio Pharma Inc (BBIO)

Before we jump into BridgeBio Pharma Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.

Want to learn more about BridgeBio Pharma Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BridgeBio Pharma Inc.

BridgeBio Pharma Inc’s Stock Price as of Market Close

As of September 11, 2024, 4:00 PM, CST, BridgeBio Pharma Inc’s stock price was $27.99.

BridgeBio Pharma Inc is down 6.67% from its previous closing price of $29.99.

During the last market session, BridgeBio Pharma Inc’s stock traded between $29.60 and $30.87. Currently, there are 187.59 million shares of BridgeBio Pharma Inc stock available for purchase.

Unfortunately, BridgeBio Pharma Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

BridgeBio Pharma Inc Stock Price History

BridgeBio Pharma Inc’s (BBIO) price is currently up 0.5% so far this month.

During the month of September, BridgeBio Pharma Inc’s stock price has reached a high of $32.06 and a low of $27.80.

Over the last year, BridgeBio Pharma Inc has hit prices as high as $44.32 and as low as $21.62. Year to date, BridgeBio Pharma Inc’s stock is up 267.32%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused BridgeBio Pharma Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 10, 2024, there were 0 analysts who downgraded BridgeBio Pharma Inc’s stock and 4 analysts who upgraded over the last month.

Additionally, you'll want to evaluate BridgeBio Pharma Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BridgeBio Pharma Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BridgeBio Pharma Inc (BBIO) by visiting AAII Stock Evaluator.

Relative Price Strength of BridgeBio Pharma Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 10, 2024, BridgeBio Pharma Inc has a weighted four-quarter relative price strength of -0.98%, which translates to a Momentum Score of 59 and is considered to be Average.

Want to learn more about how BridgeBio Pharma Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BridgeBio Pharma Inc Stock Price: Bottom Line

As of September 11, 2024, BridgeBio Pharma Inc’s stock price is $27.99, which is down 6.67% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BridgeBio Pharma Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.